Halozyme Therapeutics Stock Analysis (NASDAQ:HALO)

Add to My Stocks
$13.29 $0.05 (0.38%) HALO stock closing price Apr 21, 2017 (Closing)
Watch Robo Advisor Video of HALO Stock Analysis
Halozyme Therapeutics
Updated on : Apr 21, 2017
previous close
HALO 13.3 (0%)
S&P 500 2348.7 (0%)
Closing Price On: Apr 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
21.2%
Operating Profit
Operating Margin:
-56.7%
Sector Average:
0.6%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Cash Flow
Operating cash flow:
-$15.8M
Net Income:
-$27.4M
PROS      CONS
Long Term Growth
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
HALO PS :
11.6
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-1359%
Free Cash Flow Margin:
-41.6%
Double Tap To Exit Full Screen
0:00
/

Halozyme Therapeutics Analysis Video

110 5 2

View Halozyme Therapeutics stock analysis video. This is our HALO analyst opinion covering the buy and sell arguments for HALO stock.

Halozyme Therapeutics, Inc. Stock Rating (2.1/5)

Our Halozyme Therapeutics stock opinion is based on fundamentals of the company. This Halozyme Therapeutics stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy HALO stock?

  • The company saw a significant growth in revenue with a 5 year CAGR of 21.2%.

Should you sell HALO stock?

  • Halozyme Therapeutics registered a negative operating margin of -56.7% (average) over the Trailing Twelve Months (TTM).
  • Halozyme Therapeutics registered an average TTM Net loss of -70.2%.
  • The lack of profits renders the PE ratio useless for HALO stock.
  • HALO stock is trading at a PS multiple of 11.6, which is a negative when compared to the Medical-Biomed-Genetics industry average multiple of 4.6.
  • Halozyme Therapeutics has a negative ROE (Return On Equity) of -1359%, indicating the company is not profitable.
  • Halozyme Therapeutics has a negative FCF (Free Cash Flow) margin of -41.6%.

Comments on this video and Halozyme Therapeutics stock